Accendra Health Misses on EPS, Stock Plunges 55%

On SEP 11 2026, ACH rose by 5.94% within 24 hours to reach $0.005068, ACH dropped by 4.94% within 7 days, rose by 6.47% within 1 month, and dropped by 31.38% within 1 year.

Accendra Health Inc (ACH) recently concluded its second-quarter earnings reporting cycle, presenting a complex financial picture characterized by operational headwinds and strategic restructuring. The company’s most recent fiscal report, covering the period ending in June 2026, revealed significant deviations from analyst expectations regarding earnings per share, while revenue figures showed a slight miss against forecasts. This financial performance occurred against a backdrop of broader market adjustments, with the stock experiencing substantial volatility in the days surrounding the announcement.

The quarterly results highlighted a notable divergence between top-line revenue stability and bottom-line profitability pressures. For the quarter ended June 2026, Accendra Health reported revenue of $613.2 million. This figure fell short of the projected $632.21 million, representing a revenue surprise of -3.01%. More critically, the company posted an earnings per share (EPS) of -$0.19, a stark contrast to the forecasted positive EPS of $0.1204. This discrepancy resulted in a severe EPS surprise of -257.81%, indicating that the company’s operational costs and impairments significantly exceeded initial market projections. The market reacted sharply to these figures, with share prices dropping 55.00% in the immediate aftermath of the report.

A primary driver of the reduced profitability was identified as delays in collections stemming from intensified payer audits. These regulatory and administrative challenges reduced both revenue and adjusted EBITDA by approximately $10 million during the quarter. Consequently, the company’s Q2 adjusted EBITDA stood at $60.1 million. While the core business segments demonstrated resilience, with sleep revenue growing 5.5% and diabetes revenue increasing 4% year-over-year, other categories lagged. Respiratory, wound care, and continuous glucose monitoring (CGM) segments remained weak, contributing to an overall organic growth rate of just 2% when excluding the impact of payer delays.

Looking ahead, Accendra Health has revised its full-year guidance downward. The company now projects 2026 revenue to fall within the range of $2.45 billion to $2.55 billion, accompanied by an adjusted EBITDA forecast of $300 million to $320 million. This reduction in guidance reflects the ongoing friction with payers and the broader economic environment affecting healthcare services. Despite the near-term challenges, management outlined a path toward stabilization, expecting the fourth quarter to show significant strengthening. The firm targets normalized annual free cash flow of $100 million in 2027, contingent upon the successful launch of new partnerships and the stabilization of operational costs.

Leadership transitions and balance sheet improvements provide a counter-narrative to the operational struggles. CEO Ed Pesicka announced plans to retire by the end of 2026, signaling a potential era of new strategic direction for the organization. Furthermore, the company has actively worked to deleverage its balance sheet, having reduced debt by $400 million since March. However, management acknowledged that cash flow pressure persists due to the aforementioned payer audit challenges.

Historical context from previous quarters illustrates the volatility inherent in Accendra Health’s recent performance. In the prior quarter ending December 2025, the company had reported positive EPS of $0.21 against a forecast of $0.2212, with revenue of $708.97 million. The current quarter’s underperformance marks a significant reversal from that trend. Analysts will closely monitor the company’s ability to resolve payer disputes and execute the planned cost-stabilization measures as they approach the end of the fiscal year. The upcoming earnings release scheduled for November 4, 2026, covering the third quarter of 2026, will serve as a critical indicator of whether the strategic adjustments are yielding the expected improvements in cash flow and profitability.